2. Academic Validation
  3. Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors

Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors

  • Eur J Med Chem. 2023 Sep 19:261:115805. doi: 10.1016/j.ejmech.2023.115805.
Rehab F Ahmed 1,  Walaa R Mahmoud 1,  Nagwa M Abdelgawad 1,  Marwa A Fouad 2,  Mona F Said 3
Affiliations

Affiliations

  • 1 Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt.
  • 2 Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt; Pharmaceutical Chemistry Department, School of Pharmacy, Newgiza University, Newgiza, Km 22 Cairo-Alexandria Desert Road, Cairo, Egypt.
  • 3 Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt. Electronic address: [email protected].
PMID: 37748386 DOI: 10.1016/j.ejmech.2023.115805
Abstract

This study aimed to design potent Carbonic Anhydrase inhibitors (CAIs) based on pyrazole benzenesulfonamide core. Nine series of substituted pyrazole benzenesulfonamide compounds were synthesized with variable groups like sulphamoyl group as in compounds 4a-e, its bioisosteric carboxylic acid as in compounds 5a-e and 8e, ethyl carboxylate ester as in compounds 6a-e and 9a-e, which were designed as potential prodrugs, isothiazole ring as in compound 7, hydrazide derivative 10e, hydroxamic acid derivatives 11a-e and semicarbazide derivatives 12a-c,e. All the synthesized compounds were investigated for their Carbonic Anhydrase (CA) inhibitory activity against two human CA isoforms hCA IX and hCA XII and compared to acetazolamide (AAZ). Also, the compounds were assessed for their Anticancer activity against 60 Cancer cell lines according to the US NCI protocol. Compounds 4b, 5b, 5d, 5e, 6b, 9b, 9e and 11b revealed significant inhibitory activity against both isoforms hCA IX and hCA XII, while 6e, 9d, 11d and 11e showed significant inhibitory activity against hCA XII only compared to acetazolamide as a reference. This would highlight these compounds as promising Anticancer drugs. Moreover, compound 6e revealed a remarkable cytostatic activity against CNS Cancer cell line (SF-539; TGI = 5.58 μM), renal Cancer cell line (786-0; TGI = 4.32 μM) and breast Cancer cell line (HS 578 T; TGI = 5.43 μM). Accordingly, compound 6e was subjected to cell cycle analysis and apoptotic assay on the abovementioned cell lines at the specified GI50 (0.45, 0.89 and 1.18 μM, respectively). Also, it revealed the increment of total apoptotic cells percentage in 786-0 (53.19%), SF-539 (46.11%) and HS 578 T (43.55%) relative to the control cells (2.07, 2.64 and 2.52%, respectively). In silico prediction of BBB permeability showed that most of the calculations for compound 6e resulted as BBB (+), which is required for a compound targeting CNS. Further, the interaction of the most active compounds with the key Amino acids in the active sites of hCA IX and hCA XII was highlighted by molecular docking analysis.

Keywords

Anticancer; Benzenesulfonamide; Carbonic anhydrase inhibitors; Pyrazole.

Figures
Products